While enhanced antigen coverage may improve tumor clearance efficiency, TP53-driven genomic instability and high tumor burden appear to ultimately determine relapse risk through CAR-T-resistant clonal evolution (39, 40, 42, 43). The gene discussed is TP53; the disease is neoplasm.